The Prescription Was Written. Why Couldn’t the Patient Get the Drug?

In the United States, a physician’s decision can begin a complicated chain: benefit verification, prior authorization, documentation, appeal, affordability support, specialty-pharmacy routing, site-of-care coordination, fulfillment, and follow-up. A break anywhere in that chain can prevent an appropriate patient from receiving the prescribed therapy.

A study of 116,176 insured patients with new bempedoic acid prescriptions found that 68.9% received payer approval. Among the approved patients, 17.3% abandoned the prescription. The authors concluded that nearly half of the initially prescribed patients failed to receive therapy because of payer rejection or abandonment.^[1]

That is a product- and dataset-specific finding, not a universal benchmark for every launch. It is useful because it exposes the gap between intended treatment and actual therapy initiation.

Payers still need to assess evidence, treatment alternatives, utilization controls, budget impact, and policy language. A 2026 analysis using the Tufts Specialty Drug Evidence and Coverage database reported that, for most drugs launched in 2024, coverage policies from large commercial plans were still lacking as far as one year after approval. The authors also cite earlier research finding a median 209 days to coverage issuance.^[2]

IQVIA reported in an emerging-biopharma case study that only one in four new-to-brand patients attempting to fill a launch brand succeeded. Again, that result belongs to the analysis IQVIA described; it should not be turned into a promise or forecast for a different medicine. It reinforces the need to instrument the patient journey instead of assuming demand will automatically become treatment.^[3]

Market-access leaders may shape payer strategy, but medical, commercial, distribution, patient services, data, legal and regulatory, and external vendors all influence whether a patient begins therapy. That makes access a cross-functional operating outcome.

The Medicare Drug Price Negotiation Program offers a current example of how policy becomes operations. CMS guidance includes data exchange among participating manufacturers and dispensing entities through the Medicare Transaction Facilitator. Whatever a manufacturer’s specific exposure, the broader lesson is clear: pricing and access policy eventually become workflows, data requirements, handoffs, and accountable execution.^[4]

A manufacturer cannot outsource that accountability simply because several vendors participate in the path. A hub SLA, distribution contract, or pharmacy agreement covers a defined scope. Someone inside the manufacturer still needs to see the end-to-end journey and act when the spaces between scopes begin failing patients.

Total prescriptions and shipments matter, but they do not explain where the patient journey is breaking. Launch teams should define permitted, privacy-respecting measures for conversion, elapsed time, and fallout at each material step.

The weekly question should not stop at “How many prescriptions did we receive?” It should continue: How many patients moved to the next step? How long did that take? Where did the process stop? What reason was recorded? Who owns the correction? Do we have enough evidence to know whether this is a local workflow problem, a payer-policy issue, an affordability problem, or a design flaw?

Software can help expose friction, compare patterns, and bring a stalled handoff to the right leader’s attention. It should not invent a payer strategy or claim certainty the evidence does not support.

That evidence-honesty principle is part of how UEM is developing LaunchOS. The intended system connects risks, assumptions, decisions, dependencies, and next actions while preserving accountable human judgment. Deep payer strategy remains specialist work. The right response to an evidence gap is not a confident AI answer; it is a clearly scoped expert escalation and a decision owner.